Keratosis: Clinical Trials

67 trials for Keratosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

53 completed, 4 recruiting, 3 terminated, 2 active not recruiting. 67 Phase 1, 17 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 167Completed 53, Recruiting 4, Terminated 3, Active not recruiting 2, Not yet recruiting 2, Unknown 2, Withdrawn 1
Phase 217Completed 13, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Unknown 1

Follow Keratosis: new trials by email Literature Review of Keratosis trials Research Report on Keratosis

Trials (filtered) newest first · largest first

All 67 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Epidermal Growth Factor Receptor Inhibition for Keratinopathies
Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma
Phase 1 / Phase 2Not yet recruitingNorthwestern University442027-07-012026-08-03
5-Fluorouracil and Calcipotriene for Field Treatment of Actinic Keratoses
Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C) - Actinic Keratoses
Phase 1Not yet recruitingCedars-Sinai Medical Center962026-09-012026-10-05
An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face
Investigational drug, Photodynamic therapy - Actinic Keratosis (AK)
Phase 1RecruitingSun Pharmaceutical Industries Limited482026-08-042026-08-13
Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum
5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH) - Actinic Keratoses
Phase 1RecruitingWest Virginia University322026-02-062026-04-22
Evaluate RLS-1496 Topical Cream for Actinic Keratosis
RLS-1496 1.0% cream - Actinic Keratosis (AK)
Phase 1 / Phase 2Active not recruitingRubedo Life Sciences, Inc.242026-02-032026-08-12
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.
HW211026, Placebo - Actinic Keratosis (AK)
Phase 1RecruitingHubei Bio-Pharmaceutical Industrial Technological Institute Inc.402025-12-252026-01-06
Activation of Ameluz With BBL HEROic for the Treatment of Actinic Keratoses and Photodamage
Ameluz, Sciton HEROic - Actinic Keratoses, Photodamage
Phase 1CompletedSherrif Ibrahim102025-06-272026-01-02
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
BCX17725, Placebo - Netherton Syndrome
Phase 1Active not recruitingBioCryst Pharmaceuticals762024-09-262026-11-06
Trial to Investigate GZ21T in Healthy Volunteers
GZ21T - Actinic Keratosis
Phase 1CompletedGenzada Pharmaceuticals USA, Inc.412024-08-192026-01-28
Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome
ATR12-351 - Netherton Syndrome
Phase 1CompletedAzitra Inc.62024-06-162026-07-29
Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma
ADI PEG20, Ifosfamide, Radiotherapy - Soft Tissue Sarcoma, Sts
Phase 1TerminatedWashington University School of Medicine62024-03-142026-09-03
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
DS-2325a, Placebo - Netherton Syndrome
Phase 1 / Phase 2TerminatedDaiichi Sankyo92023-09-282026-05-14
The Effect of Topical Imipramine on Pain and Effectiveness of Topical Photodynamic Therapy
Imipramine, Vehicle - Imipramine, Photodynamic Therapy
Phase 1RecruitingWright State University242023-01-192026-08-20
ADX-629 Therapy for Sjogren-Larsson Syndrome
ADX-629 - Sjogren-Larsson Syndrome
Phase 1 / Phase 2CompletedUniversity of Nebraska82023-01-022026-05-05
A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects
DS-2325a, Placebo - Netherton Syndrome
Phase 1CompletedDaiichi Sankyo242022-11-082023-05-18
A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects
DS-2325a, Placebo - Netherton Syndrome
Phase 1CompletedDaiichi Sankyo642022-06-202023-03-06
Comparison of Nicotinamide Treatments for Actinic Keratosis
Oral Nicotinamide, topical nicotinamide - Actinic Keratoses
Phase 1CompletedFederal University of Rio Grande do Sul742022-02-012025-09-15
A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome
SXR1096 cream, Placebo cream - Netherton Syndrome
Phase 1 / Phase 2CompletedSixera Pharma92021-12-072025-12-16
Study to Evaluate Safety and Tolerability of BF-200 ALA (AmeluzĀ®) for Photodynamic Therapy in the Treatment of the Expanded Field of Actinic Keratosis on Face and Scalp
BF-200 ALA and red light LED lamp - Actinic Keratosis, Keratosis, Actinic
Phase 1CompletedBiofrontera Bioscience GmbH1122021-12-012024-10-17
Phase I/IIa Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment Period in Adult Subjects With AK
AVX001 - Actinic Keratoses
Phase 1 / Phase 2UnknownCoegin Pharma AB602021-11-022022-01-27

Showing 20 of 67. Sign in to see all of them.

Narrower conditions

Keratosis, Actinic (50)  ·  Netherton Syndrome (9)  ·  Skin Neoplasms (3)  ·  Callosities (2)  ·  Ichthyosis (2)  ·  Precancerous Conditions (2)  ·  Skin Diseases (2)  ·  Carcinoma, Basal Cell (1)  ·  Cerebral Palsy (1)  ·  Constipation (1)  ·  Darier Disease (1)  ·  Dermatitis, Atopic (1)  ·  Eczema (1)  ·  Facies (1)

Broader conditions

Skin and Connective Tissue Diseases (67)  ·  Skin Diseases (65)  ·  Neoplasms (51)  ·  Precancerous Conditions (48)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14)  ·  Genetic Diseases, Inborn (14)  ·  Congenital Abnormalities (13)  ·  Infant, Newborn, Diseases (13)  ·  Skin Abnormalities (13)  ·  Skin Diseases, Genetic (13)  ·  Ichthyosis (11)  ·  Abnormalities, Multiple (10)  ·  Ichthyosiform Erythroderma, Congenital (10)  ·  Pathological Conditions, Signs and Symptoms (4)

Interventions

3-ingenyl angelate (8)  ·  Radiotherapy (4)  ·  Fluorouracil (3)  ·  Gels (3)  ·  LEO 43204 (3)  ·  Lidocaine (3)  ·  Prilocaine (3)  ·  Aminolevulinic Acid (2)  ·  BF-200 ALA (2)  ·  Imiquimod (2)  ·  Photochemotherapy (2)  ·  calcipotriene (2)  ·  1-phenyl-3,3-dimethyltriazene (1)  ·  5-aminolevulinic acid hexyl ester (1)  ·  ADI PEG20 (1)

Sponsors

LEO Pharma (13)  ·  Peplin (5)  ·  Dong-A University (4)  ·  Daiichi Sankyo (3)  ·  Sun Pharmaceutical Industries, Inc. (3)  ·  Athenex, Inc. (2)  ·  Biofrontera Bioscience GmbH (2)  ·  G&E Herbal Biotechnology Co., LTD (2)  ·  Icahn School of Medicine at Mount Sinai (2)  ·  Wright State University (2)  ·  Aclaris Therapeutics, Inc. (1)  ·  Azitra Inc. (1)  ·  BioCryst Pharmaceuticals (1)  ·  Case Comprehensive Cancer Center (1)  ·  Cedars-Sinai Medical Center (1)

Countries

United States (40)  ·  Australia (6)  ·  Germany (5)  ·  France (4)  ·  Canada (3)  ·  South Korea (3)  ·  Netherlands (2)  ·  Sweden (2)  ·  Taiwan (2)  ·  Austria (1)  ·  Brazil (1)  ·  China (1)  ·  Denmark (1)  ·  Finland (1)  ·  Iran (1)

Top investigators

Gary Goldenberg, MD (2)  ·  Jonothan S Dosik, MD (2)  ·  Mark Lebwohl, MD (2)  ·  Mary Spellman, MD (2)  ·  Albert C Yan, MD (1)  ·  Alicia D Bucko, MD (1)  ·  Amy Paller (1)  ·  C. William Hanke, MD (1)  ·  Cameron West (1)  ·  Craig Rohan, MD (1)  ·  Daniel Siegel, MD (1)  ·  David Cutler, MD, FRCP (1)  ·  Douglas Kramer, MD (1)

Results publications

PMID 24765228, PMID 20083693, PMID 22517769, PMID 24329107, PMID 25584134, PMID 25640401, PMID 26011755, PMID 27612149, PMID 28264612, PMID 29204958, PMID 33196758, PMID 33602313, PMID 34633154, PMID 36198452

NIH funding

2014 (1), 2025 (1), P30CA043703 (1), UL1RR024150 (1)